^
    Back
    Association details:
    Biomarker:AR-V7 positive
    Cancer:Prostate Cancer
    Drug:Xtandi (enzalutamide capsule) (Androgen receptor inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients

    Excerpt:
    ...Kaplan-Meier-like curves (likely adjusted for interval censoring) will be used to display the development of AR-V7 positivity. ...
    Trial ID:
    NCT02853097
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Front Oncol
    Title:

    Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis

    Published date:
    03/18/2022
    Excerpt:
    A subgroup analysis of patients treated with androgen receptor signaling inhibitors (ARSi such as abiraterone and enzalutamide) showed a significant association of AR-V7 positivity with poorer OS, PFS, and PSA-PFS….Our data show that liquid biopsy AR-V7 is a clinically useful biomarker that is associated with poor outcomes of ARSi-treated castrate resistant PC (CRPC) patients...
    DOI:
    10.3389/fonc.2022.868031